Contacter le RP

Pour utiliser cette fonctionnalité, vous devez bénéficier d'un compte Babbler.

Télécharger ce contenu

Communiqué de presse

Toujeo® reduced risk of severe low blood sugar compared to insulin glargine

Copier le lien

VIENNA - February 14, 2018 - With the continued evolution in diabetes care and a growing understanding of today’s insulin options, Sanofi is pleased to share new real-world evidence results which showed that Toujeo® (insulin glargine 300 Units/mL) significantly reduced the risk of severe low blood sugar (hypoglycemia) events compared to the long-acting insulins, insulin glargine 100 Units/mL (Lantus) and insulin detemir. These data are being presented at the 11th Annual Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Vienna, Austria.

Hit the download button to get the document.

  • Health & Medicine
  • Medicine
  • Men's Health
  • Women's Health

Autres actualités de la marque